78463-35-1Relevant articles and documents
CANNABINOID DERIVATIVES
-
Paragraph 0133; 0151, (2021/02/12)
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such as pain, ADHD/ADD, alcohol use disorder, anxiety disorder, and dementias.
Course of Aromatisation of 5-Alkyl/aryl-2-bromocyclohex-2-en-3-ol-1-ones to Corresponding 5-Alkyl/arylresorcinols
Chandrasekharan, V.,Unnikrishnan, P.,Shah, G. D.,Bhattacharyya, S. C.
, p. 1052 - 1055 (2007/10/02)
5-Alkyl/aryl-2-bromocyclohex-2-en-3-ol-1-ones on heating undergo aromatisation through dehydrobromination to the corresponding 5-substituted resorcinols.During the course of aromatisation of 2-bromo-5-methylcyclohex-2-en-3-ol-1-one (I) and 5-n-amyl-2-bromocyclohex-2-en-3-ol-1-one (II) a few intermediates have been isolated and characterised as IV, V, VI, VIII and IX.Similar studies on 2-bromo-5-phenylcyclohex-2-en-3-ol-1-one yields two structurally different products, one with no bromine (XI) and the other with bromine in position-2 (XII), besides 5-phenylresorcinol (XIII).